CERS News and Press, Cerus Corporation From 10/29/20

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales growth in the...

Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management ...

Cerus Corporation inks FDA contract for Pathogen Reduction technology. Twist Biosciences strikes new deal for T Cell therapies. Gossamer Bio announces disappointing data for Asthma and Chronic Rhinosinusitis trials. For further details see: Cerus Inks FDA Contract, And O...

Cerus (CERS) ha been awarded a five-year contract valued at $11.1M with the FDA for the development of next-generation compounds to optimize pathogen reduction ((PR)) treatment of whole blood to reduce the risk of transfusion-transmitted infections. Pathogen reduced whole blood has the potent...

Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitte...

Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3 rd through October 5 th . This year’s Virtual Annual Meeting remains one of the largest scientific symposiu...

Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the following two conferences: The Cantor Fitzgerald...

"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," says the NIH . "There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for th...

The chief of the FDA is willing to bypass the full federal approval process in order to make a COVID-19 vaccine available as soon as possible. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news Read more ...

Investors in convalescent plasma players have experienced a bit of volatility of late related to the FDA emergency use nod to treat COVID-19 patients. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news, Read more ...